Lorlatinib raises cholesterol and triglycerides (blood fats) in most people, often within weeks, and about three in ten gain weight. Bexarotene raises triglycerides sharply; elacestrant less often. Blood tests come before and during treatment, and a statin or similar medicine is often added. On lorlatinib or bexarotene, tell your team straight away about tummy or back pain, or being sick.
Lorlatinib: in the US label, grade 3 or 4 rises in total cholesterol occurred in 18% and in triglycerides in 19% of 476 patients, with a median onset of 15 days, and 83% needed a lipid-lowering medicine started (median 17 days); the EU SmPC reports hypercholesterolaemia in 79.0% and hypertriglyceridaemia in 67.5%. Weight gain is listed in 31% (US) and 29.8% (EU). The reader's own team's protocol comes first.
Monitoring differs by label. US label: cholesterol and triglycerides before starting, at 1 and 2 months, then periodically. EU SmPC: before starting, at 2, 4 and 8 weeks, then regularly. Both say to start or increase lipid-lowering treatment; neither names a particular statin (the EU SmPC lists statins only as a class). The US label withholds lorlatinib only at grade 4 (until grade 2 or less, then the same dose; a reduced dose if severe hyperlipidaemia recurs). The EU SmPC prints the thresholds: lorlatinib continues at the same dose up to cholesterol 500 mg/dL (12.92 mmol/L) and triglycerides 1,000 mg/dL (11.4 mmol/L), and is withheld above them.
Which statin, and when, comes only from expert papers that Pfizer, the maker of lorlatinib, paid for. They prefer pitavastatin, pravastatin or rosuvastatin because of low involvement with CYP3A4, which lorlatinib induces. They disagree on when to start: at the first rise above normal (Bauer 2019, the Italian panel 2026) or by LDL cholesterol of 3.5 mmol/L or more and cardiovascular risk (the Canadian panel, Blais 2021).
Bexarotene: fasting lipids before treatment and weekly until the response is established (usually 2 to 4 weeks), then every 8 weeks (US label) or at least monthly (EU SmPC); keep triglycerides below 400 mg/dL (US) or 4.52 mmol/L (EU) to reduce the risk of what both labels call clinical sequelae (the US label points to its pancreatitis warning); both labels advise against gemfibrozil. The EU SmPC contraindicates bexarotene with a history of pancreatitis or uncontrolled lipids; the US label does not list those as contraindications.
Elacestrant: the US label asks for a lipid profile before and periodically during treatment (hypercholesterolaemia 30%, hypertriglyceridaemia 27%); the EU SmPC lists the rises as adverse reactions and has no monitoring instruction.
Weight gain on lorlatinib is managed with counselling at the start, diet and exercise, and referral to a nutritionist; the papers differ on dose changes and on GLP-1 medicines, for which they report no or limited data.
Why: The US label says increases in cholesterol and triglycerides can occur, with a median onset of 15 days, and that 83% of patients in its trials needed a lipid-lowering medicine started.
“Inform patients that serum cholesterol and triglycerides will be monitored during treatment. Advise patients that initiation or an increase in the dose of lipid-lowering agents may be required”
Why: The two labels set different schedules and neither gives a reason for its choice of weeks. The US label gives a median time to onset of 15 days. The Canadian panel (funded by Pfizer Canada) asks for 1, 2 and 3 months and then every 3 months; the Spanish panel (funded by Pfizer) says 2, 4 and 8 weeks and then every 3 to 6 months should be considered.
“Monitor serum cholesterol and triglycerides before initiating LORBRENA, 1 and 2 months after initiating LORBRENA, and periodically thereafter.”
Why: This is the instruction of both labels. The US label does not say at what level. The EU SmPC says to introduce or modify lipid-lowering therapy from mild hypercholesterolaemia (above the upper limit of normal) or mild hypertriglyceridaemia (150 to 300 mg/dL, 1.71 to 3.42 mmol/L), and lists the kinds of medicine it means: an HMG CoA reductase inhibitor (a statin), nicotinic acid, fibric acid derivatives or ethyl esters of omega-3 fatty acids.
“Initiate or increase the dose of lipid-lowering agents in patients with hyperlipidemia.”
Why: The reason the paper gives is that these three have low involvement with the liver enzymes that can interact with lorlatinib, such as CYP3A4. The US label says lorlatinib is a moderate CYP3A inducer and lowers the concentration of CYP3A substrates. The labels themselves name no particular statin. This paper was written with Pfizer employees and Pfizer-funded medical writing.
“Pitavastatin, pravastatin, or rosuvastatin should initially be considered based on their low involvement with specific CYP450 enzymes that can interact with lorlatinib (e.g., CYP3A4)”
Why: The 2019 paper says fenofibrate can be given first because it has the least involvement with the same enzymes. The Spanish panel suggests adding fenofibrate when triglycerides are above 200 mg/dL on a statin, says the combination should be used with caution because of the risk of rhabdomyolysis, and does not recommend gemfibrozil with statins; the 2019 paper says gemfibrozil is not recommended with some statins. Both papers were funded by Pfizer.
“The addition of fibrates or fish oils is considered effective in lowering triglyceride levels if treatment beyond statins is required”
Why: The EU SmPC keeps lorlatinib at the same dose, without interruption, up to and including severe rises (cholesterol 401 to 500 mg/dL, triglycerides 501 to 1,000 mg/dL), while lipid-lowering treatment is started, increased or changed. The US label has a dose rule only for grade 4. The Canadian panel (funded by Pfizer Canada) says the same in the sentence quoted.
“Lorlatinib dosage should not be modified for most patients who experience hyperlipidemia secondary to treatment.”
Why: This is the US label's rule; it gives no reason and prints no cholesterol or triglyceride figure. The EU SmPC's rule is worded by severity and prints the levels: life-threatening means cholesterol over 500 mg/dL (12.92 mmol/L) or triglycerides over 1,000 mg/dL (11.4 mmol/L); lorlatinib is withheld until the level is moderate or mild, restarted at the same dose while lipid-lowering treatment is maximised, and reduced by one dose level if a severe rise recurs despite maximal treatment. The dose levels are 75 mg and then 50 mg once daily in both labels.
“Withhold LORBRENA until recovery of hypercholesterolemia and/or hypertriglyceridemia to less than or equal to Grade 2. Resume LORBRENA at the same dose.”
Why: The EU SmPC says the risk of pancreatitis should be considered because of the raised triglycerides and possibly an effect of the medicine itself. Its patient leaflet tells people to tell their doctor immediately about pain in the back or abdomen, yellowing of the skin and eyes, nausea or vomiting. The US label has no pancreatitis warning; it lists raised lipase and amylase among laboratory abnormalities.
“Risk of pancreatitis should be considered in patients receiving lorlatinib due to concomitant hypertriglyceridemia and/or a potential intrinsic mechanism.”
European Medicines Agency (marketing authorisation holder Pfizer) 2026
Why: The Canadian panel (funded by Pfizer Canada) offers a second medicine such as ezetimibe or fenofibrate as the alternative to referral. The Italian panel (funded by Pfizer) recommends referral to a cardiovascular or lipid specialist for statin intolerance or an insufficient response to maximal treatment.
“If lipid targets are not met with an optimized dose of statin therapy, referral to a lipid specialist should be considered.”
Why: The US label says bexarotene induces substantial rises in lipids in most patients, and that the response is usually established within 2 to 4 weeks. Both labels say fasting triglycerides should be normal, or brought to normal, before treatment starts.
“Perform fasting blood lipid determinations before TARGRETIN therapy is initiated and weekly until the lipid response to TARGRETIN is established, which usually occurs within 2 to 4 weeks, and monitor at 8-week intervals thereafter.”
Why: The US label says to keep triglycerides below 400 mg/dL to reduce the risk of clinical consequences, pointing to its pancreatitis warning; the EU SmPC gives the same limit as 4.52 mmol/L and says every attempt should be made to stay below it. The EU SmPC gives the dose steps (300 to 200 and, if necessary, 100 mg per square metre a day) or stopping treatment.
“If fasting triglycerides are elevated or become elevated during treatment, institute antilipemic therapy, and if necessary, reduce or interrupt the dose of TARGRETIN.”
Why: Both labels say gemfibrozil raised the blood level of bexarotene. The US label says to avoid it in its warning and that the combination is not recommended in its interactions section; the EU SmPC says the combination is not recommended. The US label adds that atorvastatin did not change bexarotene levels, and that bexarotene halved the exposure to atorvastatin.
“Because of a potential drug-drug interaction, avoid gemfibrozil use with TARGRETIN”
Why: The US label reports acute pancreatitis, including a fatal case, associated with marked rises in fasting triglycerides, the lowest being 770 mg/dL. It tells patients to contact their healthcare provider immediately about nausea, vomiting and abdominal or back pain. The EU SmPC goes further at the start: a history of pancreatitis and uncontrolled raised cholesterol or triglycerides are contraindications.
“Interrupt TARGRETIN and evaluate if pancreatitis is suspected.”
Why: The US label reports hypercholesterolaemia in 30% and hypertriglyceridaemia in 27% of patients, with grade 3 and 4 in 0.9% and 2.2%. It does not say how often to test or what to do with a raised result. The EU SmPC lists raised triglycerides and cholesterol among the most common adverse reactions and has no monitoring instruction.
“Monitor lipid profile prior to starting and periodically while taking ORSERDU.”
Stemline Therapeutics, on DailyMed (US National Library of Medicine) 2026
Why: The paper says it is difficult to lose weight in the face of appetite stimulation, and recommends a preventive approach with food intake counselling, dietary advice and exercise. In the CROWN trial weight gain occurred in 44% of patients over 5 years and was grade 3 in 23%. The paper was sponsored by Pfizer.
“Patients and care partners should be counseled at lorlatinib initiation about the possibility of weight gain as an AE and that lorlatinib appears to stimulate appetite.”
Why: The Spanish panel (funded by Pfizer) says there is no specific medical treatment for this weight gain, recommends exercise and restriction of food intake, and says that if weight gain is associated with oedema the oedema should be managed first. It says interrupting or reducing lorlatinib is not usually needed. The sentence quoted is from the CROWN paper, which Pfizer sponsored.
“For patients in whom lifestyle modification does not appear to be sufficient, consider referral to a nutritionist or weight clinic for added patient support.”
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
No guideline with graded recommendations covers this. The firmest rules are the labels': baseline and scheduled lipid tests, lipid-lowering treatment started or increased when lipids rise, and lorlatinib withheld only at grade 4 in the US label, which the EU SmPC calls life-threatening and prints as cholesterol over 500 mg/dL or triglycerides over 1,000 mg/dL; for bexarotene, weekly fasting lipids at the start, triglycerides kept below 400 mg/dL (US) or 4.52 mmol/L (EU), gemfibrozil avoided, and, in the US label, interruption if pancreatitis is suspected. Everything about which statin to use with lorlatinib, when to start it and how to manage weight comes from expert papers that Pfizer, the maker of lorlatinib, funded, and they do not agree. On starting: the 2019 investigators' paper and the 2026 Italian panel say at the first rise above normal; the 2021 Canadian panel says total cholesterol is not a criterion and uses LDL cholesterol of 3.5 mmol/L or more, non-HDL cholesterol of 4.3 mmol/L or more, or triglycerides above 5.7 mmol/L. On the statin: pitavastatin, pravastatin or rosuvastatin (2019 paper, Spanish and Italian panels), rosuvastatin or pravastatin (Canadian panel), rosuvastatin (Latin American panel, where the other two are often unavailable); the CROWN paper lists pravastatin among the recommended statins and in the next sentences says it should be used with caution. Both positions are shown; this page does not choose.
Pfizer, on DailyMed (US National Library of Medicine) 2026 · European Medicines Agency (marketing authorisation holder Pfizer) 2026 · Bausch Health US, on DailyMed (US National Library of Medicine); SPL effective date 30 April 2020, current on DailyMed in November 2026 2020 · European Medicines Agency 2025 · Stemline Therapeutics, on DailyMed (US National Library of Medicine) 2026 · European Medicines Agency 2026 · The Oncologist (Bauer et al.; phase I investigators with three Pfizer employees among the authors; medical writing funded by Pfizer Inc.) 2019 · Current Oncology (Blais et al.; a Canadian advisory committee; funded through an unrestricted grant from Pfizer Canada Inc.) 2021 · Clinical Drug Investigation (Arriola et al.; a Spanish multidisciplinary panel; project and medical writing funded by Pfizer) 2024 · The Oncologist (Liu et al.; study sponsored by Pfizer; first draft prepared with Pfizer's AI writing tool; medical writing funded by Pfizer) 2025 · Future Oncology (Ardizzoni et al.; funded by Pfizer; two authors Pfizer employees, the other four paid consultants to Pfizer for the manuscript) 2026 · Frontiers in Oncology (Corrales et al.; consensus supported by Pfizer, which the paper says had no involvement in its content or conclusions) 2026
Where it differs: US label: before starting, at 1 and 2 months, then periodically. EU SmPC: before starting, at 2, 4 and 8 weeks, then regularly. Canadian panel (Blais 2021): a complete lipid profile at baseline, at 1, 2 and 3 months, then every 3 months; fasting is not needed unless triglycerides are above 4.5 mmol/L. Spanish panel (Arriola 2024): 2, 4 and 8 weeks and every 3 to 6 months should be considered.
Evidence: Regulatory labels, and expert opinion in papers funded by Pfizer. None gives trial evidence for one schedule over another. The EU SmPC notes that severe rises come later than first rises: a median of 201 days for cholesterol and 127 days for triglycerides.
Pfizer, on DailyMed (US National Library of Medicine) 2026 · European Medicines Agency (marketing authorisation holder Pfizer) 2026 · Current Oncology (Blais et al.; a Canadian advisory committee; funded through an unrestricted grant from Pfizer Canada Inc.) 2021 · Clinical Drug Investigation (Arriola et al.; a Spanish multidisciplinary panel; project and medical writing funded by Pfizer) 2024
Where it differs: Bauer 2019: a statin is recommended at the first sign of raised cholesterol or triglycerides. Italian panel 2026: statins should be started as soon as lipids reach grade 1 (total cholesterol above the upper limit of normal, or triglycerides at or above 150 mg/dL). Canadian panel 2021: total cholesterol is not recommended as a criterion; start for LDL cholesterol of 3.5 mmol/L or more, non-HDL cholesterol of 4.3 mmol/L or more, or triglycerides above 5.7 mmol/L, and treat everyone with a statin-indicated condition (stroke, heart attack, diabetes and others). Latin American panel 2026: start, or modify, lipid-lowering treatment for mild or moderate rises, as the EU SmPC does.
Evidence: Expert opinion, all in Pfizer-funded papers. The Canadian panel bases its thresholds on the Canadian Cardiovascular Society guideline for the general population and argues that people with ALK-positive lung cancer live long enough to be treated as people without cancer are.
The Oncologist (Bauer et al.; phase I investigators with three Pfizer employees among the authors; medical writing funded by Pfizer Inc.) 2019 · Future Oncology (Ardizzoni et al.; funded by Pfizer; two authors Pfizer employees, the other four paid consultants to Pfizer for the manuscript) 2026 · Current Oncology (Blais et al.; a Canadian advisory committee; funded through an unrestricted grant from Pfizer Canada Inc.) 2021 · Frontiers in Oncology (Corrales et al.; consensus supported by Pfizer, which the paper says had no involvement in its content or conclusions) 2026 · European Medicines Agency (marketing authorisation holder Pfizer) 2026
Where it differs: Bauer 2019, the Spanish panel and the Italian panel: pitavastatin, pravastatin or rosuvastatin. Canadian panel: rosuvastatin or pravastatin first line (pravastatin 20 mg or rosuvastatin 5 mg once daily for primary prevention; pravastatin 40 mg or rosuvastatin 20 to 40 mg for secondary prevention), with people already on another statin switched to an equivalent dose. Latin American panel: rosuvastatin, because pitavastatin and pravastatin are not available in many of its countries. CROWN paper: pitavastatin, pravastatin and rosuvastatin are the recommended statins, but it also says that pitavastatin and rosuvastatin could be used in the trial without dose adjustment, that pravastatin, fluvastatin and atorvastatin should be used with caution and may need dose adjustment, and that lovastatin and simvastatin are not recommended. In CROWN itself the commonest lipid medicines were rosuvastatin (55%), atorvastatin (19%) and fenofibrate (11%).
Evidence: A reasoned choice from how each statin is metabolised, not from a trial comparing statins in people on lorlatinib. All papers were funded by Pfizer. Neither label names a particular statin.
The Oncologist (Bauer et al.; phase I investigators with three Pfizer employees among the authors; medical writing funded by Pfizer Inc.) 2019 · Clinical Drug Investigation (Arriola et al.; a Spanish multidisciplinary panel; project and medical writing funded by Pfizer) 2024 · Future Oncology (Ardizzoni et al.; funded by Pfizer; two authors Pfizer employees, the other four paid consultants to Pfizer for the manuscript) 2026 · Current Oncology (Blais et al.; a Canadian advisory committee; funded through an unrestricted grant from Pfizer Canada Inc.) 2021 · Frontiers in Oncology (Corrales et al.; consensus supported by Pfizer, which the paper says had no involvement in its content or conclusions) 2026 · The Oncologist (Liu et al.; study sponsored by Pfizer; first draft prepared with Pfizer's AI writing tool; medical writing funded by Pfizer) 2025
Where it differs: US label: withhold at grade 4 until grade 2 or less; same dose; reduced dose if severe hyperlipidaemia recurs. EU SmPC: withhold above cholesterol 500 mg/dL or triglycerides 1,000 mg/dL until moderate or mild; same dose with maximal lipid-lowering treatment; one dose level lower if a severe rise recurs despite it. Canadian panel: clinicians may consider withholding at grade 4, and may consider a dose reduction if it recurs despite optimal treatment. CROWN paper: for severely raised lipids, pause lorlatinib until total cholesterol is below 400 mg/dL and triglycerides below 500 mg/dL, then resume at the same dose.
Evidence: Regulatory labels and expert opinion. In the US label's trials about 4% and 7% of patients needed a temporary stop, and 1% and 3% a dose reduction, for cholesterol and triglycerides.
Pfizer, on DailyMed (US National Library of Medicine) 2026 · European Medicines Agency (marketing authorisation holder Pfizer) 2026 · Current Oncology (Blais et al.; a Canadian advisory committee; funded through an unrestricted grant from Pfizer Canada Inc.) 2021 · The Oncologist (Liu et al.; study sponsored by Pfizer; first draft prepared with Pfizer's AI writing tool; medical writing funded by Pfizer) 2025
Where it differs: Testing after the lipid response is established: every 8 weeks (US) or at intervals no less than monthly (EU). Triglyceride ceiling: 400 mg/dL (US) or 4.52 mmol/L (EU). Contraindications: the EU SmPC lists a history of pancreatitis, uncontrolled hypercholesterolaemia and uncontrolled hypertriglyceridaemia; the US label does not, and instead says people with risk factors for pancreatitis may be at greater risk. The EU SmPC says people with CTCL who have risk factors for pancreatitis should not be treated unless the potential benefit outweighs the risk, and that raised cholesterol should be managed according to current medical practice. Gemfibrozil: the US label says to avoid it in its hyperlipidaemia warning and that it is not recommended in its interactions section; the EU SmPC says it is not recommended. Pancreatitis: the US label says to interrupt bexarotene and evaluate if it is suspected; the EU SmPC has no matching sentence.
Evidence: Regulatory labels. The US label reports that in the 300 mg per square metre group 60% of patients were given lipid-lowering medicines and that atorvastatin was used in 48% of patients with CTCL.
Bausch Health US, on DailyMed (US National Library of Medicine); SPL effective date 30 April 2020, current on DailyMed in November 2026 2020 · European Medicines Agency 2025
Where it differs: The US label has a dyslipidaemia warning and asks for a lipid profile before and periodically during treatment. The EU SmPC has no such warning or instruction; it lists raised triglycerides and cholesterol among the most common adverse reactions. Neither has a dose rule written for lipids: each has a general table by grade. On rosuvastatin, the EU SmPC reports that elacestrant raised its exposure (45% for peak level, 23% for overall exposure) and says the dose of medicines carried by BCRP should be reduced according to their own product information; the US label says to reduce such medicines when small changes in level may lead to serious reactions.
Evidence: Regulatory labels; no management paper for elacestrant lipid changes was looked for beyond them.
Stemline Therapeutics, on DailyMed (US National Library of Medicine) 2026 · European Medicines Agency 2026
Where it differs: Dose: Bauer 2019 says dose modifications should be applied in more severe cases of weight gain; the Spanish panel says interruption or reduction is not usually needed; the Italian panel says a gain of 20% or more may warrant management and that dose reduction is generally not advised unless lifestyle changes fail to relieve weight-related discomfort; the Latin American panel says temporary interruption may be considered for progressive, clinically significant gain (for example more than 20%). GLP-1 medicines: the Spanish panel says there are no data on semaglutide or other incretins for lorlatinib weight gain; the CROWN paper says data are limited; the Italian panel says they may be used upon expert approval with monitoring; the Latin American panel says they may be contemplated, with referral to an endocrinologist advised.
Evidence: Expert opinion in Pfizer-funded papers. In CROWN, 95% of grade 2 or 3 weight gain events had no dose change or medicine, and of the 52 patients with no medical intervention 35% had resolution and 49% no resolution.
The Oncologist (Bauer et al.; phase I investigators with three Pfizer employees among the authors; medical writing funded by Pfizer Inc.) 2019 · Clinical Drug Investigation (Arriola et al.; a Spanish multidisciplinary panel; project and medical writing funded by Pfizer) 2024 · Future Oncology (Ardizzoni et al.; funded by Pfizer; two authors Pfizer employees, the other four paid consultants to Pfizer for the manuscript) 2026 · Frontiers in Oncology (Corrales et al.; consensus supported by Pfizer, which the paper says had no involvement in its content or conclusions) 2026 · The Oncologist (Liu et al.; study sponsored by Pfizer; first draft prepared with Pfizer's AI writing tool; medical writing funded by Pfizer) 2025
Where it differs: NICE NG238, written for the general population and not for people on cancer medicines, says to refer for urgent specialist review when triglycerides are above 20 mmol/L and not explained by alcohol or poor diabetic control, and for 10 to 20 mmol/L to repeat a fasting test (after 5 days, within 2 weeks) and seek specialist advice if the level stays above 10 mmol/L. The EU SmPC for lorlatinib acts on a different figure (11.4 mmol/L) and by pausing the cancer medicine; the US label prints no figure.
Evidence: NICE recommendations dated 2014 within the 2023 guideline; NICE does not grade its recommendations.
National Institute for Health and Care Excellence (general guidance for England; not oncology guidance) 2023 · European Medicines Agency (marketing authorisation holder Pfizer) 2026
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Lorlatinib, EU SmPC: lipids before starting, at 2, 4 and 8 weeks, and regularly “cholesterol and triglycerides should be monitored before initiation of lorlatinib; 2, 4 and 8 weeks after initiating lorlatinib; and regularly thereafter.” | Regulatory label; not graded | European Medicines Agency (marketing authorisation holder Pfizer) 2026 |
| Lorlatinib, EU SmPC: what counts as lipid-lowering therapy “Lipid-lowering therapy may include: HMG CoA reductase inhibitor, nicotinic acid, fibric acid derivatives, or ethyl esters of omega-3 fatty acids.” | Regulatory label; not graded | European Medicines Agency (marketing authorisation holder Pfizer) 2026 |
| Lorlatinib, US label: 83% needed a lipid-lowering medicine started “Eighty-three percent of patients required initiation of lipid-lowering medications, with a median time to onset of start of such medications of 17 days.” | Regulatory label; not graded | Pfizer, on DailyMed (US National Library of Medicine) 2026 |
| Lorlatinib, US label: reduced dose if severe hyperlipidaemia recurs “If severe hypercholesterolemia and/or hypertriglyceridemia recurs, resume LORBRENA at a reduced dose.” | Regulatory label; not graded | Pfizer, on DailyMed (US National Library of Medicine) 2026 |
| Lorlatinib induces CYP3A, lowering levels of medicines that CYP3A clears “LORBRENA is a moderate CYP3A inducer. Concomitant use of LORBRENA decreases the concentration of CYP3A substrates” | Regulatory label; not graded | Pfizer, on DailyMed (US National Library of Medicine) 2026 |
| Canadian panel: rosuvastatin and pravastatin first line “rosuvastatin and pravastatin are recommended as first-line lipid-lowering therapy in patients treated with lorlatinib” | Expert panel algorithm; not graded (funded by an unrestricted grant from Pfizer Canada) | Current Oncology (Blais et al.; a Canadian advisory committee; funded through an unrestricted grant from Pfizer Canada Inc.) 2021 |
| Canadian panel: total cholesterol is not a criterion for starting “TC itself is not recommended as a criterion for the initiation of a lipid-lowering therapy according to the CCS and other current guidelines” | Expert panel algorithm; not graded (funded by an unrestricted grant from Pfizer Canada) | Current Oncology (Blais et al.; a Canadian advisory committee; funded through an unrestricted grant from Pfizer Canada Inc.) 2021 |
| Canadian panel: withholding at grade 4 is something clinicians may consider “Clinicians may consider temporarily withholding lorlatinib therapy in patients who experience grade 4 hyperlipidemia” | Expert panel algorithm; not graded (funded by an unrestricted grant from Pfizer Canada) | Current Oncology (Blais et al.; a Canadian advisory committee; funded through an unrestricted grant from Pfizer Canada Inc.) 2021 |
| Spanish panel: statins whose metabolism lorlatinib does not affect “the statins pitavastatin, pravastatin, and rosuvastatin have a very low risk of interaction with the cytochrome P450 (CYP) enzymes involved in the metabolism of lorlatinib” | Expert consensus; not graded (funded by Pfizer) | Clinical Drug Investigation (Arriola et al.; a Spanish multidisciplinary panel; project and medical writing funded by Pfizer) 2024 |
| Spanish panel: gemfibrozil with statins is not recommended “The use of gemfibrozil in combination with statins is not recommended due to the risk of hepatic and renal toxicity” | Expert consensus; not graded (funded by Pfizer) | Clinical Drug Investigation (Arriola et al.; a Spanish multidisciplinary panel; project and medical writing funded by Pfizer) 2024 |
| Spanish panel: no specific medical treatment for lorlatinib weight gain; exercise and restriction of food intake “Although there is no specific medical treatment for this weight gain, physical exercise and restriction of food intake are recommended” | Expert consensus; not graded (funded by Pfizer) | Clinical Drug Investigation (Arriola et al.; a Spanish multidisciplinary panel; project and medical writing funded by Pfizer) 2024 |
| Spanish panel: manage oedema first when it accompanies weight gain “If weight gain is associated with edema, treatment of the edema should be managed first.” | Expert consensus; not graded (funded by Pfizer) | Clinical Drug Investigation (Arriola et al.; a Spanish multidisciplinary panel; project and medical writing funded by Pfizer) 2024 |
| Italian panel: start statins at grade 1 “Treatment with statins should be started as soon as lipid levels reach grade 1 toxicity” | Expert panel; not graded (funded by Pfizer; two authors Pfizer employees) | Future Oncology (Ardizzoni et al.; funded by Pfizer; two authors Pfizer employees, the other four paid consultants to Pfizer for the manuscript) 2026 |
| Italian panel: dose reduction for weight gain is generally not advised “Lorlatinib dose reduction is generally not advised unless lifestyle changes fail to alleviate weight-related discomfort.” | Expert panel; not graded (funded by Pfizer; two authors Pfizer employees) | Future Oncology (Ardizzoni et al.; funded by Pfizer; two authors Pfizer employees, the other four paid consultants to Pfizer for the manuscript) 2026 |
| CROWN paper: pravastatin, fluvastatin and atorvastatin with caution “Pravastatin, fluvastatin, and atorvastatin should be used with caution during lorlatinib treatment, and dose adjustment of these statins may be necessary.” | Trial report with expert commentary; not graded (sponsored by Pfizer) | The Oncologist (Liu et al.; study sponsored by Pfizer; first draft prepared with Pfizer's AI writing tool; medical writing funded by Pfizer) 2025 |
| Latin American panel: rosuvastatin first line “Patients with hyperlipidemia should be treated with rosuvastatin as a first-line therapy (pitavastatin and pravastatin are not available in many Latinoamerican countries).” | Delphi consensus; not graded (supported by Pfizer) | Frontiers in Oncology (Corrales et al.; consensus supported by Pfizer, which the paper says had no involvement in its content or conclusions) 2026 |
| Bexarotene, EU SmPC: triglycerides below 4.52 mmol/l “Every attempt should be made to maintain triglyceride levels below 4.52 mmol/l in order to reduce the risk of clinical sequelae.” | Regulatory label; not graded | European Medicines Agency 2025 |
| Bexarotene, US label: triglycerides below 400 mg/dL “Maintain triglyceride levels below 400 mg/dL to reduce the risk of clinical sequelae” | Regulatory label; not graded | Bausch Health US, on DailyMed (US National Library of Medicine); SPL effective date 30 April 2020, current on DailyMed in November 2026 2020 |
| Bexarotene, EU SmPC: gemfibrozil is not recommended “concomitant administration of gemfibrozil with bexarotene is not recommended (see section 4.5).” | Regulatory label; not graded | European Medicines Agency 2025 |
| Elacestrant, EU SmPC: reduce the dose of medicines carried by BCRP, such as rosuvastatin “BCRP substrates should be reduced according to their Summary of Product Characteristics.” | Regulatory label; not graded | European Medicines Agency 2026 |
| General guidance for England: urgent specialist review above 20 mmol/L “Refer for urgent specialist review if a person has a triglyceride level of more than 20 mmol per litre that is not a result of excess alcohol intake or poor glycaemic control.” | NICE does not grade recommendations | National Institute for Health and Care Excellence (general guidance for England; not oncology guidance) 2023 |
| Megestrol tablets, which are not one of this page's medicines: the label was read to see whether weight gain on progestins could be covered here. It says weight gain is frequent and gives no instruction for it, so progestins are left out “Weight gain is a frequent side effect of megestrol. This gain has been associated with increased appetite and is not necessarily associated with fluid retention.” | Regulatory label; not graded | Major Pharmaceuticals, on DailyMed (US National Library of Medicine) 2025 |
Shares High blood sugar on PI3K, AKT and mTOR inhibitors: prevention, monitoring and treatment, Dose reduction, interruption and discontinuation.
Shares Drug, herbal and food interaction review for anticancer treatment, Heart risk assessment and monitoring before, during and after heart-toxic cancer treatment.
Shares Drug, herbal and food interaction review for anticancer treatment, Heart risk assessment and monitoring before, during and after heart-toxic cancer treatment.
Shares CTCAE toxicity grading (grade 3-4 adverse events), Fluid retention, swelling and pleural effusion on kinase inhibitors and MET-targeted drugs.
Shares Drug, herbal and food interaction review for anticancer treatment, Heart risk assessment and monitoring before, during and after heart-toxic cancer treatment.
Shares Fluid retention, swelling and pleural effusion on kinase inhibitors and MET-targeted drugs.
Shares Drug, herbal and food interaction review for anticancer treatment, Dose reduction, interruption and discontinuation.